Date: 2015-10-28
Type of information: R&D agreement
Compound: transmembrane immunomodulatory protein (TIP™) technology
Company: Kite Pharma (USA - CA) Alpine Immune Sciences (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D licensing
Action mechanism:
Disease:
Details: * On October 27, 2015, Kite Pharma announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences, a privately-held biotechnology company, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. AIS will grant Kite an exclusive license to two programs from its transmembrane immunomodulatory protein (TIP™) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates. This collaboration will accelerate Kite\'s efforts to establish the next generation of engineered T cell therapies specifically designed to overcome the inhibitory mechanisms present in the tumor microenvironment.
Financial terms: Under the terms of the collaboration, Kite will make an upfront payment to AIS of $5 million and additional payments to support AIS\' research. AIS will be eligible to receive milestone payments based upon the successful achievement of pre-specified research, clinical, and regulatory milestones totaling $530 million plus low single-digit royalty payments on product sales. Kite will receive an exclusive, worldwide license to research, develop and commercialize engineered autologous T cell therapies incorporating two programs coming from the AIS platform.
Latest news:
